AML patients with higher CD123 were usually exhibited increased resistance to chemotherapeutic drugs (Ehninger et al., 2014) and have lower complete remission (CR) rate, higher relapse rate and negative prognosis (Thokala et al., 2016). This evidence concerns the gene IL3RA and acute myeloid leukemia.